In a regulatory filing, Coupang disclosed that its director Benjamin Sun sold 373K shares of common stock on December 1st in a total transaction size of $7.47M.

General Motors' BrightDrop announced it had entered its first international market, Canada, adding DHL Express Canada to its customer portfolio. The company also announced production of the BrightDrop Zevo 600 electric delivery vans had begun at GM's CAMI Assembly plant in Ontario, making the facility Canada's first large-scale EV factory. BrightDrop offers a suite of products including the Zevo electric delivery vans, the Trace eCarts, and the BrightDrop Core software platform to reduce carbon emissions from last mile delivery while reducing urban congestion. The business launched in 2021 with a nearly $800M investment from its parent company GM to convert the CAMI Assembly plant to BrightDrop's high-volume EV production facility. Entering the Canadian market is BrightDrop's latest effort to address the $250B last-mile delivery industry, particularly as companies around the world set goals to electrify their fleets and optimize operations. DHL Express Canada plans to add its first BrightDrop Zevo electric delivery vans to its fleet early next year.

In an interview on CNBC's Mad money, Michael Skipworth said, "We've got plenty of inventory." He expects a favorable commodity backdrop for 2023 with strong comp growth. "We're set up for a 19th quarter of consecutive growth," he added.

LGI Homes "announced it closed 412 homes in November 2022. As of November 30, 2022, the company had 92 active selling communities."

Textron "announced that Bell Textron Inc., a Textron company, has been awarded the development contract for the U.S. Army's Future Long-Range Assault Aircraft program. The award is based on Bell's V-280 Valor tiltrotor that was developed and tested as part of the Joint Multi-Role Technology Demonstrator program that began in 2013. The V-280 progressed through design, manufacturing, and more than three years of rigorous flight testing that provided extensive data validating the technical and operational advantages of the aircraft for the long-range assault mission. The initial contract refines the weapon system design, sustainment, digital enterprise, manufacturing, systems integration, flight-testing, and airworthiness qualification."

Mirati Therapeutics announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the tolerability and feasibility of a concurrent combination regimen of a KRASG12C inhibitor and a PD-1/L1 checkpoint inhibitor. The KRYSTAL-7 and KRYSTAL-1 trials represent the largest dataset evaluating a KRASG12C inhibitor in combination with a PD-1/L1 checkpoint inhibitor as a first-line treatment for patients with NSCLC harboring a KRASG12C mutation. 75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months. Treatment-related adverse events were Grade 1-2 (39%), Grade 3 (40%) and Grade 4 (4%); there were no Grade 5 TRAEs observed. TRAEs led to discontinuation of both adagrasib and pembrolizumab in 2 patients and only pembrolizumab in 2 patients; there were no patients who discontinued only adagrasib due to a TRAE. Increases in alanine transaminase/ aspartate transaminase were consistent with either agent as a monotherapy with Grade 3 TRAEs being highest grade and total incidence of Grade 3 liver function test increases of 9%. Median time from onset to an increase in ALT and AST was 26 and 37 days, respectively and only 1 patient experienced new onset treatment-related ALT/AST increase after 3 months. Of patients who were clinically evaluable and received at least one on-study scan, adagrasib and pembrolizumab demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate of 49%. In a subset of response-evaluable patients enrolled at least 6 months prior to the data cutoff date, 6 of 26 clinical responses occurred at second on-study scan or later, and the ORR was 56%. 7 evaluable patients enrolled in the KRYSTAL-1 Phase 1b cohort reported an ORR of 57% and a disease control rate of 100%. The four patients who responded maintained response for over nine months while two continued to receive treatment and remain in response beyond 18 months. Safety in the KRYSTAL-1 Phase 1b cohort was consistent with what has been observed in KRSTYAL-7 and demonstrated a manageable safety profile with no Grade 4-5 TRAEs. "Initial results across all cohorts suggest the concurrent combination of adagrasib and pembrolizumab may provide a chemotherapy-free option for treatment-naive NSCLC with a manageable safety profile and encouraging clinical activity," said Pasi A. Janne, MD, PhD, Dana Farber Cancer Institute. "Across all evaluated cohorts, liver-related TRAEs were predominantly low grade and occurred early in treatment, with limited new onset after 3 months."

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 in alcohol use disorder were published in The American Journal of Drug and Alcohol Abuse. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California at Los Angeles and was funded by the National Institute on Drug Abuse. Topline results from a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in 52 non-treatment seeking individuals with AUD found that MN-166 reduced heavy drinking and attenuated neural cue-reactivity compared to placebo. Neural and peripheral inflammation has been implicated in the development and maintenance of AUD, as evidenced by increased inflammation in such individuals. A secondary analysis of this study was performed to determine if participants with elevated peripheral levels of proinflammatory proteins, specifically C-reactive protein, would show a greater benefit from MN-166 as assessed by clinical and biological outcomes.

Highlights: GOL's total supply increased 29.7%. Total seats increased 29.2% and the number of departures increased by 26.5%. GOL's total demand increased by 28.5% and the load factor was 81.3%. GOL's domestic supply increased 19.6% and demand increased by 18.7%. GOL's domestic load factor was 81.8%. The volume of departures increased by 22.1% and seats increased by 24.8%. GOL's international supply was 350M, the demand was 269M and international load factor was 76.9%.